Olmesartan Medoxomilo + Hidroclorotiazida Atolme (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil combined with hydrochlorothiazide is used to manage high blood pressure through the renin‑angiotensin system and diuretic pathways.

• Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Heart failure with reduced ejection fraction: assists in fluid management and blood pressure control when used with other guideline‑directed therapies.
• Diabetic nephropathy: helps slow progression of kidney damage by controlling systemic pressure.
• Post‑myocardial infarction: contributes to secondary prevention by maintaining target blood pressure levels.
• Chronic kidney disease stage 3–4: used as part of a regimen to limit proteinuria and hypertension.
• Resistant hypertension: added when blood pressure remains uncontrolled despite three antihypertensive agents.

• Olmesartan medoxil selectively blocks the angiotensin II type‑1 (AT‑1) receptor, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting natriuresis and diuresis. The combined actions reduce peripheral vascular resistance and plasma volume, producing an additive antihypertensive effect.

Olmesartan medoxil with hydrochlorothiazide may exhibit a range of adverse reactions.

Common Side Effects

• Dizziness.
• Headache.
• Fatigue.
• Cough.
• Increased urination.
• Electrolyte imbalance (low potassium).

Serious or Rare Side Effects

• Angio‑ema.
• Severe dehydration.
• Acute kidney injury.
• Hyperkalemia.
• Hepatic dysfunction.
• Blood dyscrasia.

Patients prescribed Olmesartan medoxil + hydrochlorothiazide should be evaluated before treatment.

• Monitor blood pressure and electrolytes:
• Assess renal function and liver function at baseline and periodically.
• Avoid use in pregnancy and while breast feeding.
• Caution in elderly patients with volume‑depleted states.
• Store at below 25°C:

 ");

•  
•   
• t  
• t